Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 18, 2023.

A peer-reviewed analysis revealed critical gaps in care for patients with Parkinson disease in the United States, including disparities affecting women, people of color, and residents of rural areas.

Elevated caregiver depression risk corresponds to increased emergency department usage, hinting at a pivotal link between caregiver well-being and patient healthcare utilization.

Patients on IPX203 received less doses than those on traditional immediate-release carbidopa/levodopa and demonstrated 0.53 more hours of good ON time per day than IR CD/LD.

A new platform showed the ability to effectively detect patients with synucleinopathies using serum samples, improving the time and accuracy for diagnosis of specific neurodegenerative diseases such as Parkinson disease.

The neurosurgeon at Allegheny Health Network provided perspective on how GammaTile therapy is revolutionizing neurosurgery and post-operative processes of brain tumors.

In addition to showing a safe and tolerable safety profile, patients who underwent the procedure showed a 7-point median improvement on the upper extremity Fugl-Meyer Assessment when used in combination with physical rehabilitation.

The phase 2 clinical trial ACTIVATE investigating BIA 28-6156 for Parkinson disease is currently screening for patients in North America and with the Europe-based study beginning sometime during the third quarter of 2023.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the dilemma of stratifying patients with Parkinson disease based on various criteria and emphasized the need for a consensus on classification. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 11, 2023.

The director of movement disorders at the Banner Sun Health Research Institute talked about alternative approaches for treating essential tremor beyond medications, and developments in the diagnostic criteria for Lewy body disorders. [WATCH TIME: 5 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of July 2023, compiled all into one place by the NeurologyLive® team.

Patients who continued on active treatment into the open-label extension saw continued improvements in their condition after 14 weeks.

ANPD001, an autologous cell therapy derived from patient-derived iPSCs, is designed to replace lost dopamine neurons in patients with Parkinson disease.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed patient reluctance towards new treatments for Parkinson disease and the role of education in defining treatment expectations for patients. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 4, 2023.

The director of movement disorders at the Banner Sun Health Research Institute discussed the challenges in diagnosing atypical Parkinsonian disorders and the potential role of biomarkers in improving diagnostic accuracy. [WATCH TIME: 5 minutes]

Positive data from the 25 mg cohort study exploring Larimar Therapeutics’ CTI-1601 has been submitted to the FDA, with a meeting scheduled with the agency later this quarter to discuss steps for a phase 2 trial.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed the current state of treatment for Parkinson disease and gene therapy as a promising treatment for the management of the disease. [WATCH TIME: 5 minutes]

Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.

Phase 1 trial results investigating UB-312 revealed target engagement of aggregated alpha-synuclein in cerebrospinal fluid of patients with Parkinson disease, providing validation of the vaccine technology to selectively target aggregated, toxic forms of neurodegenerative proteins.